Pharmaco Company Profile
What is the competitive landscape for PHARMACO
PHARMACO has eight approved drugs.
There are nineteen US patents protecting PHARMACO drugs.
Summary for Pharmaco
| US Patents: | 19 |
| Tradenames: | 8 |
| Ingredients: | 7 |
| NDAs: | 8 |
| Patent Litigation for Pharmaco: | See patent lawsuits for Pharmaco |
| PTAB Cases with Pharmaco as petitioner: | See PTAB cases with Pharmaco as petitioner |
Drugs and US Patents for Pharmaco
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacosmos | COSELA | trilaciclib dihydrochloride | POWDER;INTRAVENOUS | 214200-001 | Feb 12, 2021 | RX | Yes | Yes | 8,598,186 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Pharmaco | ETODOLAC | etodolac | TABLET;ORAL | 210704-001 | Dec 16, 2020 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Pharmacosmos | COSELA | trilaciclib dihydrochloride | POWDER;INTRAVENOUS | 214200-001 | Feb 12, 2021 | RX | Yes | Yes | 10,085,992 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pharmacosmos | COSELA | trilaciclib dihydrochloride | POWDER;INTRAVENOUS | 214200-001 | Feb 12, 2021 | RX | Yes | Yes | 12,168,666 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pharmaco
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pharmaco | NALFON | fenoprofen calcium | CAPSULE;ORAL | 017604-003 | Approved Prior to Jan 1, 1982 | 3,600,437 | ⤷ Start Trial |
| Pharmaco | NALFON | fenoprofen calcium | CAPSULE;ORAL | 017604-002 | Approved Prior to Jan 1, 1982 | 3,600,437 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Pharmaco Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Ukraine | 103373 | ⤷ Start Trial |
| Japan | 6337083 | ⤷ Start Trial |
| Hungary | E052617 | ⤷ Start Trial |
| China | 103936745 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pharmaco Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1666481 | C 2017 029 | Romania | ⤷ Start Trial | PRODUCT NAME: TOFACITINIB, OPTIONAL SUB FORMA UNEI SARI ACCEPTABILE FARMACEUTIC, INCLUSIV SAREA CITRAT 3-((3R,4R)-4-METIL-3-{METIL-(7H-PIROLO[2,3-D]PIRIMIDIN-4-IL)-AMINO]PERIDINIL)-3-OXO-PROPIONITRIL; NATIONAL AUTHORISATION NUMBER: EU/1/17/1178; DATE OF NATIONAL AUTHORISATION: 20170322; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1178; DATE OF FIRST AUTHORISATION IN EEA: 20170322 |
| 0480717 | 19/1999 | Austria | ⤷ Start Trial | PRODUCT NAME: MONTELUKAST ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE MONTELUKASTNATRIUM; NAT. REGISTRATION NO/DATE: 1-22765 UND 1-22766 19981030; FIRST REGISTRATION: FI 12766 UND 12767 19970825 |
| 1666481 | PA2017025,C1666481 | Lithuania | ⤷ Start Trial | PRODUCT NAME: TOFACITINIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALE, ISKAITANT CITRATO DRUSKAAA; REGISTRATION NO/DATE: EU/1/17/1178 20170322 |
| 1666481 | CR 2017 00035 | Denmark | ⤷ Start Trial | PRODUCT NAME: TOFACITINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HERUNDER CITRAT-SALTET; REG. NO/DATE: EU/1/17/1178/001-003 20170324 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
